24226 Federal Register / Vol. 65, No. 80 / Tuesday, April 25, 2000 / Notices

United States Attorney, District of

Hawaii, Room 6100, PJKK Federal

Building, 300 Ala Moana Boulevard,

Honolulu, Hawaii 96850. You may also

obtain a copy of the consent decree by

mail from the Consent Decree Library,

P.O. Box 7611, Washington, DC 20044.

Your request for a copy of the consent

decree should refer to United States v.

BHP Petroleum Americas Refining, Inc.,

now known as Tesoro Hawaii

Corporation, Civil Action No. 00–00264

DAE (D. Hawaii), and DOJ No. 90–5–2–

1–2124, and must include a check for

$14.00 (25 cents per page reproduction

cost) payable to the ‘‘Consent Decree

Library.’’

Joel Gross,

Chief, Environmental Enforcement Section,

Environment and Natural Resources Division.

[FR Doc. 00–10229 Filed 4–24–00; 8:45 am]

BILLING CODE 4410–15–M

DEPARTMENT OF JUSTICE

Antitrust Division

[Civil Action No. 95–1221 (CRR)]

United States District Court for the

District of Columbia, United States of

America, Plaintiff, vs. American Bar

Association, Defendant

Take notice that The United States of

America and the American Bar

Association (‘‘ABA’’) have filed a joint

motion for an order modifying the final

judgment entered by the United States

District Court for the District of

Columbia on June 25, 1996 (‘‘Final

Judgment’’). The parties have agreed to

modify the Final Judgment to reflect

changes in the law school accreditation

process necessitated by regulations

promulgated by the Department of

Education (‘‘DOE’’) pursuant to the

Higher Education Act, 20 U.S.C. 1099(b)

(1998). Prior to the entry of the order

modifying the Final Judgment, the Court

and the parties will consider public

comments. Any such comments on the

proposed modification described in this

Notice must be filed within 60 days

following the date of this Notice. The

Complaint, Final Judgment and

proposed modification are further

described below.

The Complaint, filed on June 27,

1995, alleged that the ABA had violated

Section 1 of the Sherman Act in its law

school accreditation activities. The

Complaint alleged that the ABA had

restrained competition among

professional personnel at ABAapproved law schools by fixing their

salaries and other compensation levels

and working conditions, and by limiting

competition from non-ABA-Approved

schools. The ABA and United States

agreed to a settlement, and on June 25,

1996, the Court entered the Final

Judgment, enjoining the ABA from

fixing compensation and from enforcing

a boycott of non-ABA approved schools.

Moreover, because the Complaint

alleged that the ABA had allowed the

accreditation process to be misused by

law school personnel with a direct

economic interest in its outcome, the

Final Judgment ordered the BA to take

a number of steps to limit the influence

of law school personnel in the

accreditation process, including having

the ABA’s House of Delegates review

and approve certain aspects of the

accreditation process.

After the Final Judgment was entered,

DOE determined that allowing the

House of Delegates to act as the final

decision-maker for accreditation

activities did not conform to provisions

of the Higher Education Act and DOE

regulations. Consequently, the ABA, in

order to retain its status as a DOErecognized accreditation agency, has

modified the House’s role, and the

parties to the Final Judgment have

agreed that the Court should make

appropriate modifications to the Final

Judgment so that it conforms to the DOE

requirements.

Under the joint proposal, Sections

IV(A) and VIII(D) of the Final Judgment

will be modified and a new Section

IV(M) will be added. As modified, the

Judgment will be consistent with DOE’s

rules which prevent the House of

Delegates from being the final decisionmaker in establishing the standards,

interpretations, and rules used to

evaluate law schools or in determining

whether a school receives or maintains

its accreditation. Consistent with DOE

requirements, the House of Delegates

will maintain a role in reviewing

standards, interpretations, and rules and

in reviewing accreditation decisions and

can remand such actions to the Council

of the ABA’s Section on Legal Education

and Admissions to the Bar, the DOErecognized accrediting agency.

The United States has filed with the

Court a memorandum setting forth its

position with respect to modifying the

Final Judgment. Copies of the

Complaint, the Final Judgment, the

Modification to the Final Judgment, the

Stipulation containing the parties’

tentative consent, the Joint Motion, the

United States’ memorandum and all

other papers filed in connection with

this motion are available for inspection

at the Office of the Clerk of the United

States District Court for the District of

Columbia, 333 Constitution Avenue,

NW, Washington, DC 20001, and at

Suite 215, Antitrust Division,

Department of Justice, 325 Seventh

Street, NW, Washington, DC 20530,

(Telephone: (202) 514–2481).

Interested persons may submit

comments regarding this matter within

sixty (60) days of the date of this notice.

Such comments, and responses thereto,

will be filed with the Court. Comments

should be directed to Nancy M.

Goodman, Chief, Computers and

Finance Section, Room 9500, 600 E

Street, NW, Antitrust Division,

Department of Justice, Washington, DC

20530, (telephone: (202) 307–6122)

M.J. Moltenbrey,

Director of Civil Non-Merger Enforcement.

[FR Doc. 00–10231 Filed 4–24–00; 8:45 am]

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances;

Notice of Application

Pursuant to Section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with Section

1301.34 of Title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on January 31, 2000,

Mallinckrodt, Inc., Mallinckrodt &

Second Streets, St. Louis, Missouri

63147, made application by renewal to

the Drug Enforcement Administration to

be registered as an importer of the basic

classes of controlled substances listed

below:

Drug Schedule

Phenylacetone (8501) .............. II

Coca Leaves (9040) ................. II

Opium, raw (9600) .................... II

Opium poppy (9650) ................. II

Poppy Straw Concentrate

(9670) .................................... II

The firm plans to import the listed

controlled substances to bulk

manufacture controlled substances.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of these basic classes of

controlled substances may file written

comments on or objections to the

Federal Register / Vol. 65, No. 80 / Tuesday, April 25, 2000 / Notices 24227

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections or

requests for a hearing may be addressed,

in quintuplicate, to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, DC

20537. Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than (30 days from publication).

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1301.34(b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 4374–46

(September 23, 1975), all applicants for

registration to import the basic classes

of any controlled substances in

Schedule I or II are and will continue to

be required to demonstrate to the

Deputy Assistant Administrator, Office

of Diversion Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1301.34(a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: April 18, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–10206 Filed 4–24–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated December 13, 1999,

and published in the Federal Register

on December 28, 1999, (64 FR 248),

Polaroid Corporation, 1265 Main Street,

Building W6, Waltham, Massachusetts

02451, made application to the Drug

Enforcement Administration (DEA) to

be registered as a bulk manufacturer of

2,5-dimethoxyamphetamine (7396), a

basic class of controlled substance listed

in Schedule I.

The firm plans to manufacture 2,5-

dimethoxyamphetamine for conversion

into a non-controlled substance.

No comments or objections have been

received. DEA has considered the

factors in title 21, United States Code,

section 823(a) and determined that the

registration of Polaroid Corporation to

manufacture 2,5-

dimethoxyamphetamine is consistent

with the public interest at this time.

DEA has investigated Polaroid

Corporation to ensure that the

company’s registration is consistent

with the public interest. The

investigation included inspection and

testing of the company’s physical

security systems, verification of the

company’s compliance with State and

local laws, and a review of the

company’s background and history.

Therefore, pursuant to 21 U.S.C. 823

and 28 CFR. 0.100 and 0.104, the

Deputy Assistant Administrator, Office

of Diversion Control, hereby orders that

the application submitted by the above

firm for registration as a bulk

manufacturer of the basic class of

controlled substance listed above is

granted.

Dated: April 6, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–10210 Filed 4–24–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances;

Notice of Application

Pursuant to section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with section

1301.34 of title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on January 24, 2000, Roche

Diagnostics Corporation, 9115 Hague

Road, Indianapolis, Indiana 46250,

made application to the Drug

Enforcement Administration to be

registered as an importer of the basic

classes of controlled substances listed

below:

Drug Schedule

Lysergic acid diethylamide (7315) I

Tetrahydrocannabinols (7370) ..... I

Cocaine (9041) ............................. II

Methadone (9250) ........................ II

Morphine (9300) ........................... II

The firm plans to import the listed

controlled substances for the

manufacture of diagnostic products.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of these basic classes of

controlled substances may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections or

requests for a hearing may be addressed,

in quintuplicate, to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, DC

20537, Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than May 25, 2000.

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1301.34(b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import the basic classes

of any controlled substances in

Schedule I or II are and will continue to

be required to demonstrate to the

Deputy Assistant Administrator, Office

of Diversion Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1301.34(a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: April 6, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–10207 Filed 4–24–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to section 1301.33(a) of title

21 of the Code of Federal Regulations

(CFR), this is notice that on January 24,

2000, Roche Diagnostics Corporation,

9115 Hague Road, Indianapolis, Indiana

46250, made application by renewal to

the Drug Enforcement Adminsitraiton

(DEA) for registration as a bulk

manufacturer of the basic classes of

controlled substances listed below: